CAS NO: | 75580-37-9 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
Cas No. | 75580-37-9 |
别名 | BBM-928A |
化学名 | Luzopeptin A |
Canonical SMILES | CC(O[C@@H]1[C@@](N2N=CC1)([H])C(NCC(N(C)CC(N(C)[C@@H](C(O)(C)C)C(OC[C@@H](NC(C3=NC4=CC=C(OC)C=C4C=C3O)=O)C(N5[C@]([C@@H](OC(C)=O)CC=N5)([H])C(NCC(N(C)CC(N(C)[C@@H](C(O)(C)C)C(OC[C@@H](NC(C6=NC(C=CC(OC)=C7)=C7C=C6O)=O)C2=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)= |
分子式 | C64H78N14O24 |
分子量 | 1427.4 |
溶解度 | Soluble in DMSO;Soluble in dimethyl formamide |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Luzopeptin A is a cyclic depsipeptide antibiotic. A depsipeptide is a peptide in which one or more of its amide groups are replaced by the corresponding ester, or more generally, is a molecule that has both peptide and ester linkages in proximity in the same amino acid-containing small molecule or chain. In vitro: Previous study found that luzopeptin A treatment could produce additional DNA bands which were the products of type II biintercalation. The types of restriction fragments involved were identified. Maximal type II biintercalation occurred at a luzopeptin A/DNA range of 0.14 to 0.18, at which more than 50% of the total DNA molecules were involved. Type II products were gradually converted to type I products upon prolonged incubation at 37 degrees, maybe due to the tendency for intermolecular bonds to disrupt. Echinomycin treatment failed to produce type II products, probably because of a DNA-binding affinity weaker than that of luzopeptin A [1]. In vivo: Animal study showed that when administered as a suspension in 0.9% NaCl solution, luzopeptin A demonstrated good activity against i.p. B16 melanoma and i.p. P388 leukemia and weak activity versus i.v. P388, i.p. L1210 leukemia, Lewis lung, and Madison 109 lung carcinomas. In terms of tumor cell kill, luzopeptin A induced net reductions in the body burdens of L1210 and P388 leukemias following single-drug injections but failed to yield net reductions following multiple-injection therapies [2]. Clinical trial: So far, no clinical study has been conducted. References: |